ArticleThe Journal of pediatrics2009
Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.
Article in The Journal of pediatrics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02626182 (Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease), which is not on this map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 270 citations in OpenAlex.
- Inhaled Nitric Oxide for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Systematic Review and Narrative Synthesis.Neonatology · 2025Pooled it
- Sildenafil for pulmonary hypertension in neonates.The Cochrane database of systematic reviews · 2017Pooled it
- Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial.Clinical drug investigation · 2019Trial
- Article
- Pulmonary Hemodynamics and Long-Term Outcomes in Children with Pulmonary Hypertension-Associated Bronchopulmonary Dysplasia.The Journal of pediatrics · 2026Article
- Pulmonary vasodilator use in very preterm infants in United States children's hospitals.Journal of perinatology : official journal of the California Perinatal Association · 2025Observational
- The rationale of using angiotensin receptor blocker instead of pulmonary vasodilators to treat pulmonary hypertension in bronchopulmonary dysplasia: a case report and literature review.Frontiers in pediatrics · 2025Article
- Novel scoring tool of hypoxemic respiratory failure and pulmonary hypertension for defining severity of persistent pulmonary hypertension of newborn.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
- Cardiopulmonary physiological effects of diuretic therapy in preterm infants with chronic pulmonary hypertension.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
- Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.Children (Basel, Switzerland) · 2023Article
- Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia.Acta paediatrica (Oslo, Norway : 1992) · 2023Article
- A multidisciplinary approach to severe bronchopulmonary dysplasia is associated with resolution of pulmonary hypertension.Frontiers in pediatrics · 2023Article
- Serotonin-deficient neonatal mice are not protected against the development of experimental bronchopulmonary dysplasia or pulmonary hypertension.Physiological reports · 2022Article
- Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension.Seminars in fetal & neonatal medicine · 2022Review
- Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia.Pediatric research · 2022Review
- Pulmonary hypertension in the child with bronchopulmonary dysplasia.Pediatric pulmonology · 2021Review
- Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension.The Journal of clinical investigation · 2021Article
- Treatment of pulmonary arterial hypertension in children.Cardiovascular diagnosis and therapy · 2021Review
- Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn.Clinics in perinatology · 2021Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine the clinical course and outcomes of infants with chronic lung disease (CLD) and pulmonary hypertension (PH) who received prolonged sildenafil therapy. STUDY
designWe conducted a retrospective review of 25 patients <2 years of age with CLD in whom sildenafil was initiated for the treatment of PH while they were hospitalized from January 2004 to October 2007. Hemodynamic improvement was defined by a 20% decrease in the ratio of pulmonary to systemic systolic arterial pressure or improvement in the degree of ventricular septal flattening with serial echocardiograms.
resultsChronic sildenafil therapy (dose range, 1.5-8.0 mg/kg/d) was initiated at a median of 171 days of age (range, 14-673 days of age) for a median duration of 241 days (range, 28-950 days). Twenty-two patients (88%) achieved hemodynamic improvement after a median treatment duration of 40 days (range, 6-600 days). Eleven of the 13 patients with interval estimates of systolic pulmonary artery pressure with echocardiogram showed clinically significant reductions in PH. Five patients (20%) died during the follow-up period. Adverse events leading to cessation or interruption of therapy occurred in 2 patients, 1 for recurrent erections, and the other had the medication held briefly because of intestinal pneumatosis.
conclusionThese data suggest that chronic sildenafil therapy is well-tolerated, safe, and effective for infants with PH and CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.